Aquestive Therapeutics Inc (NAS:AQST)

$ 3.13 -0.09 (-2.8%) Market Cap: 285.39 Mil Enterprise Value: 244.36 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 55/100

Q3 2024 Aquestive Therapeutics Inc Earnings Call Transcript
Nov 05, 2024

$4.76 (-7.67%)

Earnings
Q2 2024 Aquestive Therapeutics Inc Earnings Call Transcript
Aug 07, 2024

$3.43 (+0.88%)

Earnings
Q1 2024 Aquestive Therapeutics Inc Earnings Call Transcript
May 08, 2024

$3.09 (-8.73%)

Earnings
Q4 2023 Aquestive Therapeutics Inc Earnings Call Transcript
Mar 06, 2024

$5.03 (+20.05%)

Earnings
Q3 2023 Aquestive Therapeutics Inc Earnings Call Transcript
Nov 07, 2023

$1.71 (+4.91%)

Earnings
Q2 2023 Aquestive Therapeutics Inc Earnings Call Transcript
Aug 08, 2023

$1.94 (-5.37%)

Earnings
Aquestive Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Q1 2023 Aquestive Therapeutics Inc Earnings Call Transcript
May 03, 2023

$1.68 (+20.86%)

Earnings
Q4 2022 Aquestive Therapeutics Inc Earnings Call Transcript
Mar 08, 2023

$0.85

Earnings
Q3 2022 Aquestive Therapeutics Inc Earnings Call Transcript
Nov 02, 2022

$0.84 (-1.81%)

Earnings
Aquestive Therapeutics Inc Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen Call Transcript
Sep 27, 2022
Aquestive Therapeutics Receives FDA Tentative Approval for Libervant™ (diazepam) Buccal Film Call Transcript
Aug 31, 2022
Q2 2022 Aquestive Therapeutics Inc Earnings Call Transcript
Aug 03, 2022

$0.838 (-4.74%)

Earnings
Aquestive Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022
Q1 2022 Aquestive Therapeutics Inc Earnings Call Transcript
May 04, 2022

$1.42 (+3.65%)

Earnings
Q4 2021 Aquestive Therapeutics Inc Earnings Call Transcript
Mar 09, 2022

$2.8 (-0.71%)

Earnings
Q3 2021 Aquestive Therapeutics Inc Earnings Call Transcript
Nov 03, 2021

$5.9 (+10.07%)

Earnings
Aquestive Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Q2 2021 Aquestive Therapeutics Inc Earnings Call Transcript
Aug 04, 2021

$3.68 (+13.23%)

Earnings
Q1 2021 Aquestive Therapeutics Inc Earnings Call Transcript
May 05, 2021

$3.85 (+5.48%)

Earnings
Aquestive Therapeutics Inc Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event Transcript
Mar 25, 2021
Q4 2020 Aquestive Therapeutics Inc Earnings Call Transcript
Mar 10, 2021

$4.75 (+6.26%)

Earnings
Q3 2020 Aquestive Therapeutics Inc Earnings Call Transcript
Nov 05, 2020

$5.49 (+3.98%)

Earnings
Aquestive Therapeutics Inc Conference Call Transcript
Sep 25, 2020
Q2 2020 Aquestive Therapeutics Inc Earnings Call Transcript
Aug 05, 2020

$5.92 (+7.83%)

Earnings
Aquestive Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2020
Q1 2020 Aquestive Therapeutics Inc Earnings Call Transcript
May 06, 2020

$4.32 (-4.00%)

Earnings
Q4 2019 Aquestive Therapeutics Inc Earnings Call Transcript
Mar 12, 2020

$1.92 (-34.69%)

Earnings
Aquestive Therapeutics Inc Investor & Analyst Libervant Update Forum and Webcast Transcript
Dec 09, 2019
Q3 2019 Aquestive Therapeutics Inc Earnings Call Transcript
Nov 06, 2019

$5.23 (+23.64%)

Earnings
Q2 2019 Aquestive Therapeutics Inc Earnings Call Transcript
Aug 07, 2019

$3.52 (+11.75%)

Earnings
Q1 2019 Aquestive Therapeutics Inc Earnings Call Transcript
May 08, 2019

$4.52 (-17.06%)

Earnings
Q4 2018 Aquestive Therapeutics Inc Earnings Call Transcript
Mar 14, 2019

$6.37 (-15.96%)

Earnings

Q2 2020 Aquestive Therapeutics Inc Earnings Call Transcript

Aug 05, 2020 / 12:00PM GMT

Release Date Price: $5.92 (+7.83%)

Transcript 10-Q8-K

Operator

Good morning, and welcome to the Aquestive Therapeutics Second Quarter 2020 Conference Call.

(Operator Instructions)

As a reminder, this call will be recorded. I would now like to introduce your host for today's conference, Ms. Stephanie Carrington, Westwicke Investor Relations. You may begin.

Stephanie Carrington

ICR, LLC - SVP

Thank you, operator. Good morning, and welcome to today's call to review Aquestive Therapeutics' Results for the Second Quarter 2020 and Business Highlights. On today's call, I am joined by Keith Kendall, President and Chief Executive Officer; and John Maxwell, Chief Financial Officer, who are going to provide an overview of recent business developments and performance in the second quarter. Additional members of the leadership team will be available for Q&A.

In total, we expect today's call to last approximately 60 minutes. As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.